Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854811 | 0.84 | HTR6 (0.39) | SSTR4HTR6 | |
| SCHEMBL1966529 | 0.82 | HTR6 (0.41) | HTR6 | |
| SCHEMBL28175563 | 0.79 | HTR6 (0.36) | HTR6 | |
| SCHEMBL9557656 | 0.71 | HTR6 (0.36) | HTR6 | |
| SCHEMBL1386444 | 0.70 | MEN1 (0.33) | — | |
| SCHEMBL1956709 | 0.69 | — | — | |
| SCHEMBL9557652 | 0.67 | — | — | |
| SCHEMBL21422730 | 0.67 | — | — | |
| Glycine SCHEMBL3500554 | 0.67 | MEN1 (0.45) | — | |
| SCHEMBL28881685 | 0.66 | HTR6 (0.40) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576083-B2 | Morpholinyl piperidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2005107469-A3 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005107469-A2 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005107469-A2 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | SLC1A1, SLC1A2, SLC6A7 | SSTR4 1988/4885SLC6A1 9/4885GABRA5 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.